Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
Central nervous system involvement by metastasis occurs in 3% to 4% of patients with NSCLC and 9% of NSCLC patients with EGFR mutations. Involvement of the lepto-meninges, thin membranous connective tissue layers with blood vessels that surround the brain and spinal cord, accounts for deteriorating neurologic function, mental status changes and poor prognosis in these patients, but can be difficult to diagnose with current methods.
This prospective study evaluated results from
"Testing the cerebrospinal fluid of patients for metastases to the central nervous system is a key component of our oncology testing business," said
About the IASLC 2020 Lung Cancer Hot Topic Meeting: Liquid Biopsy
There have been numerous advances in liquid biopsy since this event's advent in 2018, and the concept of a "blood-first" approach—superseding or replacing tissue biopsy—is a current topic of much debate and discussion. This innovative virtual conference will bring together international and multidisciplinary experts in the field of liquid biopsy in lung cancer to present and discuss current technology and best practices for clinical applications based on available data.
About the IASLC
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the ability of our tests to provide clinically actionable information and the ability of
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-study-results-from-target-selector-testing-in-the-cerebrospinal-fluid-of-patients-with-lung-cancer-at-the-iaslc-liquid-biopsy-meeting-301143765.html